Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TYLOX-325 vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen and oxycodone combination. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Oxycodone is a mu-opioid receptor agonist, activating descending pain pathways and altering pain perception.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Management of moderate to severe pain requiring an opioid analgesic,Severe pain uncontrolled by non-opioid analgesics
Relief of moderate to moderately severe pain
1-2 capsules (oxycodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum 12 capsules per day.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Oxycodone: 3-5 hours (extended-release preparation); terminal half-life 4.5-5.5 hours. Clinical context: repeated dosing may lead to accumulation; half-life prolongation in elderly, renal or hepatic disease.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Acetaminophen is primarily metabolized via conjugation (glucuronidation and sulfation) and via CYP2E1 (minor pathway forming toxic NAPQI). Oxycodone is metabolized via CYP3A4 (to noroxycodone) and CYP2D6 (to oxymorphone).
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Renal: acetaminophen metabolites (60-70% as glucuronide conjugate, 20-30% as sulfate conjugate, 5-10% as cysteine conjugate, 5% unchanged). Oxycodone: renal (primarily metabolites, <10% unchanged); biliary/fecal: minor (oxycodone metabolites).
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Acetaminophen: 10-25% (albumin). Oxycodone: 45% (primarily albumin).
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
Acetaminophen: 0.9-1.0 L/kg; extensive distribution. Oxycodone: 2.6-3.6 L/kg; high tissue penetration including CNS.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Acetaminophen: oral 85-90%. Oxycodone: oral 60-87% (variable first-pass metabolism).
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
e GFR 30-60 m L/min: administer at reduced frequency (e.g., every 8-12 hours); e GFR <30 m L/min: avoid use or use with extreme caution (reduce dose by 50% and monitor); hemodialysis: not recommended due to acetaminophen accumulation.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Child-Pugh A (mild): no adjustment necessary; Child-Pugh B (moderate): reduce oxycodone dose by 50% and limit acetaminophen to ≤2000 mg/day; Child-Pugh C (severe): contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Not approved for children <18 years; weight-based dosing: oxycodone 0.05-0.15 mg/kg/dose (max 5 mg) and acetaminophen 10-15 mg/kg/dose (max 650 mg) orally every 4-6 hours as needed; total daily acetaminophen ≤75 mg/kg/day.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Initiate at lowest dose (e.g., 1 capsule every 6 hours); titrate cautiously; avoid in patients with renal impairment or hepatic dysfunction; monitor for opioid-induced constipation, respiratory depression, and acetaminophen hepatotoxicity; consider alternative non-opioid analgesics if feasible.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; interaction with alcohol.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Respiratory depression, opioid-induced hyperalgesia, adrenal insufficiency, severe hypotension, seizures, serotonin syndrome, hepatotoxicity, risk of overdose with acetaminophen, risks of use in patients with head injury or increased intracranial pressure.
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Hypersensitivity to acetaminophen or oxycodone, significant respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction, paralytic ileus.
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Avoid alcohol. High-fat meals may delay absorption of oxycodone but do not significantly alter overall exposure. No specific food restrictions beyond alcohol.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Pregnancy Category C. Oxycodone crosses placenta. First trimester: risk of neural tube defects not established; avoid unless benefit outweighs risk. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome (NOWS). Third trimester: high doses near term may cause neonatal respiratory depression.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Oxycodone is excreted in breast milk; M/P ratio approximately 3.4:1. American Academy of Pediatrics recommends cautious use; monitor infant for drowsiness, respiratory depression. Acetaminophen is compatible with breastfeeding. Overall, risk to infant is low with short-term maternal use.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
Increased clearance and volume of distribution during pregnancy may require dose adjustment. Pharmacokinetic changes: oxycodone clearance increases up to 1.6-fold in third trimester; acetaminophen clearance unchanged. Clinical monitoring of pain and adverse effects recommended; dose may need upward titration.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
Tylox-325 contains oxycodone and acetaminophen. Avoid in patients with known hypersensitivity to opioids or acetaminophen. The maximum daily acetaminophen dose is 4 g; monitor for hepatotoxicity. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Coadministration with CNS depressants (e.g., benzodiazepines) increases risk of respiratory depression. Constipation is common; prescribe stool softeners prophylactically. Discontinue gradually to avoid withdrawal.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Take exactly as prescribed; do not exceed 4 grams of acetaminophen per day from all sources.,Avoid alcohol while taking this medication.,May cause dizziness or drowsiness; do not drive or operate heavy machinery until you know how this medication affects you.,Do not take with other medications containing acetaminophen without consulting your doctor.,Contact your doctor if you experience signs of liver damage (yellow skin/eyes, dark urine, abdominal pain) or respiratory depression (slow/shallow breathing).,Store securely out of reach of others; this medication can be habit-forming and may be a target for misuse.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TYLOX-325 vs ANEXSIA, answered by our medical review team.
TYLOX-325 is a Opioid analgesic combination that works by Acetaminophen and oxycodone combination. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Oxycodone is a mu-opioid receptor agonist, activating descending pain pathways and altering pain perception.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TYLOX-325 and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TYLOX-325 is: 1-2 capsules (oxycodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum 12 capsules per day.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TYLOX-325 and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TYLOX-325 is classified as Category C. Pregnancy Category C. Oxycodone crosses placenta. First trimester: risk of neural tube defects not established; avoid unless benefit outweighs risk. Second/third trimester: chronic. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.